XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2023
Mar. 25, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K/A    
Amendment Flag true    
Amendment Description In this Amendment No. 1 on Form 10-K/A (“Amendment No. 1”), unless the context requires otherwise, “Eledon”, the "Company", "we", "our", and "us" means Eledon Pharmaceuticals, Inc. (formerly Novus Therapeutics, Inc.) and all of its wholly-owned subsidiaries.This Amendment No. 1 amends the Annual Report on Form 10-K of Eledon Pharmaceuticals, Inc. for the fiscal year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on March 28, 2024 (the “Original Report”). The Company is filing Amendment No. 1 to present the information required by Part III (Items 10, 11, 12, 13 and 14) of Form 10-K as we will not file our definitive proxy statement within 120 days of the end of our fiscal year ended December 31, 2023. In addition, in accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Item 15 of Part IV of the Original Report is being amended and restated solely to include as exhibits the certifications of our principal executive officer and principal financial officer required by Rule 13a-14(a) under the Exchange Act. Except as otherwise expressly noted herein, this Amendment No. 1 does not amend, modify or update any other information set forth in the Original Report. Furthermore, this Amendment No. 1 does not change any previously reported financial results, nor does it reflect events occurring after the filing date of the Original Report. Information not affected by this Amendment No. 1 remains unchanged and reflects the disclosures made at the time the Original Report was filed. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Report and our other filings with the SEC. Certain capitalized terms used and not otherwise defined in this Amendment No. 1 have the meanings given to them in the Annual Report.    
Document Period End Date Dec. 31, 2023    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Trading Symbol ELDN    
Entity Registrant Name ELEDON PHARMACEUTICALS, INC.    
Entity Central Index Key 0001404281    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Voluntary Filers No    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Emerging Growth Company false    
Entity File Number 001-36620    
Entity Tax Identification Number 20-1000967    
Entity Address, Address Line One 19900 MacArthur Boulevard    
Entity Address, Address Line Two Suite 550    
Entity Address, City or Town Irvine    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 92612    
City Area Code (949)    
Local Phone Number 238-8090    
Entity Incorporation, State or Country Code DE    
Document Annual Report true    
Document Transition Report false    
ICFR Auditor Attestation Flag false    
Title of 12(b) Security Common Stock, $0.001 par value    
Security Exchange Name NASDAQ    
Entity Common Stock, Shares Outstanding   24,813,130  
Entity Public Float     $ 25,607,310
Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

None